Keros Therapeutics (KROS) Non Operating Income (2019 - 2025)
Keros Therapeutics posted quarterly Non Operating Income of $273000.0 for Q4 2025, up 101.59% year-on-year from $135425.6 in Q4 2024, and up 207.91% on a QoQ basis from -$253000.0 in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Non Operating Income data on file, last reported at $273000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income rose 101.59% year-over-year to $273000.0; the trailing twelve-month figure through Dec 2025 stood at $6.6 million (up 197.35% YoY), and the FY2025 full-year result was -$539000.0, up 43.5% from the prior year.
- Non Operating Income for Q4 2025 stood at $273000.0, up from -$253000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $9.3 million in Q4 2022 and bottomed at -$17.2 million in Q4 2024.
- The 5-year median for Non Operating Income is -$62000.0 (2021), against an average of $269050.0.
- The widest annual swing landed in 2022, when Non Operating Income soared 12529.33%; it then sank 280.23% in 2023.
- A 5-year view of Non Operating Income shows it stood at -$75000.0 in 2021, then jumped by 12529.33% to $9.3 million in 2022, then plunged by 217.39% to -$10.9 million in 2023, then tumbled by 57.23% to -$17.2 million in 2024, then jumped by 101.59% to $273000.0 in 2025.
- The last three Non Operating Income figures came in at $273000.0 (Q4 2025), -$253000.0 (Q3 2025), and $6.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | 273,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 273,000.00 |
| Sep 30, 2025 | -253,000.00 |
| Jun 30, 2025 | 6.90 Mn |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -17.21 Mn |
| Sep 30, 2024 | 5.70 Mn |
| Jun 30, 2024 | 5.18 Mn |
| Mar 31, 2024 | -437,000.00 |
| Dec 31, 2023 | -10.94 Mn |
| Sep 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | -155,000.00 |
| Mar 31, 2023 | 3.07 Mn |
| Dec 31, 2022 | 9.32 Mn |
| Sep 30, 2022 | 762,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | -59,000.00 |
| Dec 31, 2021 | -75,000.00 |
| Sep 30, 2021 | -138,000.00 |
| Jun 30, 2021 | -80,000.00 |
| Mar 31, 2021 | -65,000.00 |
| Dec 31, 2020 | 1.65 Mn |
| Sep 30, 2020 | -88,000.00 |
| Jun 30, 2020 | 158,000.00 |
| Mar 31, 2020 | -68,000.00 |
| Dec 31, 2019 | -23,000.00 |
| Sep 30, 2019 | 15,000.00 |
| Jun 30, 2019 | -202,000.00 |
| Mar 31, 2019 | -325,000.00 |